Trials in Ventura, California
Here are the top 10 medical studies for colorectal cancer in Ventura, California
Popular Filters
Phase 3 Trials
Chemotherapy
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
Small Molecule Drug
Sotorasib + Panitumumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
PD-L1 Inhibitor
XL092 + Atezolizumab vs Regorafenib for Colorectal Cancer
Recruiting2 awardsPhase 3
Santa Monica, California
This trial is testing a combination of two drugs, XL092 and atezolizumab, against another treatment in patients with a specific type of colorectal cancer that has spread and not responded to standard treatments. The goal is to see if the new combination can better stop cancer growth and help the immune system fight the cancer.
Chemotherapy
Nivolumab-relatlimab Combo for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
PD-1 Inhibitor
Dostarlimab for Colon Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Trials With No Placebo
Chemotherapy
Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing to see if tucatinib in combination with other drugs is more effective than standard of care drugs at treating participants with HER2 positive colorectal cancer.
CAR T-cell Therapy
Allogeneic CAR-T Cells for Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial tests a new therapy using modified immune cells in adults with advanced cancers. The treatment aims to target and destroy cancer cells with a specific marker found in various cancers, including breast cancer.
Kinase Inhibitor
Encorafenib + Cetuximab and Pembrolizumab for Colorectal Cancer
Recruiting1 awardPhase 2
Los Angeles, California
This trial is studying the effects of 3 drugs given together for colorectal cancer that has spread, is hypermutatable, or has impaired DNA repair. 1 drug is given by IV, and the other 2 are taken orally at home.
Monoclonal Antibodies
NGM831 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing a new drug called NGM831 alone or with other drugs in patients with advanced or spreading solid tumors. The goal is to see if these treatments can help stop the cancer or help the immune system fight it better. One of the drugs being tested has been widely studied and used in various cancers, showing significant improvements in survival rates and being effective in combination with other treatments.
Small Molecule Drug
Sotorasib + Panitumumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.
XL092 + Immuno-Oncology Agents for Solid Tumors
Recruiting1 awardPhase 1
Solvang, California
This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.